In the last few years the incidence of fungal infections in the immunocompromised host has increased greatly. The emergence of these pathogens has been followed by both primary drug resistance and the secondary development of azole-resistant isolates of Candida albicans and Cryptococcus neoformans (11, 18, 32, 40) . In some severely immunocompromised patients such as those with AIDS, the concept of lifelong suppressive therapy has been advocated. It is clear that new antifungal agents with potent and broad-spectrum fungicidal activity are needed for the effective management of these infections.
The search for new antifungal agents led to the examination of a series of dicationic aromatic compounds related to pentamidine (Table 1 ). This class of compounds has been shown to have excellent activity against a number of pathogenic organisms, including Giardia lamblia (4, 5) , Toxoplasma gondii (24) , Pneumocystis carinii (10, 34, 36, 38) , Plasmodium falciparum (6) , Leishmania mexicana amazonensis (6) , and Trypanosoma brucei (21) . In addition, pentamidine has previously been reported to have an inhibition effect on the growth of C. albicans (33) and C. neoformans (3) .
The current work describes the antifungal activities of analogues of pentamidine (Table 1) , metabolites of pentamidine (Table 2) , and a series of compounds derived from the highly potent anti-P. carinii bis-benzimidazoles (Table 3 ) (38) . All of the compounds were screened for activity against C. albicans and C. neoformans. Selected compounds that showed high levels of activity against C. albicans and C. neoformans were tested for their activities against additional strains of these fungi as well as other important pathologic yeasts and clinically important molds (Table 4 ). The screening was carried out according to a broth macrodilution reference method for in vitro antifungal susceptibility testing of yeast by the National Committee for Clinical Laboratory Standards (29) . Examination of the results from these studies reveal several compounds with potent and broad-spectrum antifungal activities.
(quintet, 1H, J ϭ 6.0 Hz), 2.04 to 2.0 (m, 2H), 1.73 to 1.65 (m, 4H), 1.57 to 1.49 (m, 2H). 13 C NMR (DMSO-d 6 ): 160.4, 148.5, 134.1, 129.4, 127.3, 118.9, 114.6, 54.1, 31.2, 23.5. The 4-(N-cyclopentylamidino)-2-nitroaniline (5.0 g, 0.02 mol; mp, 238 to 240°C dec) was used directly without further characterization (5.0 g, 0.02 mol), and 1.0 g of 10% Pd/C in 130 ml of dry methanol was subjected to hydrogenation at 50 lb/in 2 for approximately 1 h. The catalyst was filtered over Celite and washed with hot methanol, the solvent of the filtrate was removed under reduced pressure, the residue was triturated with dry ether, and the solid was filtered and dried under vacuum at 45°C for 24 h. The yield of light brown hygroscopic solid was 3.91 g (72%); mp, 170 to 178°C. 1 
2,5-Bis[2-(5-amidino)benzimidazoyl]furan hydrochloride (compound 35).
A solution of furan-2,5-dicaboxaldehyde (28) (0.8 g 2 mmol), 4-amidino-1,2-phenylene diamino hydrochloride hydrate (0.8 g, 4 mmol), and 1,4-benzoquinone (0.432 g, 4 mmol) in ethanol (40 ml) was heated at reflux for 4 h (under nitrogen) (1) . The reaction mixture was cooled to room temperature and the dark solid was collected by filtration, washed with cold ethanol and anhydrous ether, and dried to yield 0.55 g (71%) of the free base. This solid was dissolved slowly in hot ethanol (300 ml) and filtered. The filtrate volume was reduced to 70 ml and was acidified with HCl-saturated ethanol. After standing overnight in the refrigerator, the green solid was collected by filtration, washed with anhydrous ether, and dried under vacuum to yield 0.4 g (52%) yield of a solid; mp, Ͼ300°C. 
2,5-Bis{2-[5-(2-imidazolino)]benzimidazoyl}furan hydrochloride (compound 36).
A protocol similar to that described above was used for the condensation of 2,5-furandicarboxaldehyde (28) and 2-(3,4-diaminophenyl)imidazoline (17, 35) to give a 38% yield of a green powder; mp, Ͻ300°C. 
2,5-Bis[2-(5-N-cyclopentylamidino)benzimidazoyl]furan hydrochloride (compound 38).
A protocol similar to that described above was used for the condensation of 2,5-furandicarboxaldehyde (28) and 4-(N-cyclopentylamidino)-1,2-phenylene diamine to give a 77% yield of a yellow-green powder, mp, 287 to 289°C dec. 1 
2,5-Bis[2-(5-N-isopropylamidino)benzimidazoyl]pyrrole hydrochloride (compound 41).
A protocol similar to that described above was used for the condensation of pyrrole-2,5-dicarboxaldehyde and 4-(N-isopropylamidino)-1,2-phenylene diamine (17, 35) to yield 79% of a yellow-green solid; mp, 287 to 289°C dec. 1 pound 42) . A protocol similar to that described above was used for the condensation of 4-(N-cyclopentylamidino)-1,2-phenylene diamine with pyrrole-2,5-dicarboxaldehyde (27) 
2,5-Bis[2-(5-N-isopropylamidino)benzimidazoyl]thiophene hydrochloride (compound 46).
A protocol similar to that described above was used for the condensation of 2,5-thiophenedicarboxaldehyde and 4-(N-isopropylamidino)-1,2-phenylene diamine (17, 35) to give a 75% yield of a green-yellow solid; mp, 290 to 292°C dec. 
2,6-Bis{2-[5-(2-imidazolino)]benzimidazoyl}pyridine hydrochloride (compound 51).
A protocol similar to that described above was used for the condensation of 2,6-pyridine carboxyaldehyde and 2-(3,4-diaminophenyl)imidazoline (17, 35) to give an 85% yield of a solid; mp, Ͼ300°C. 
2,6-Bis[2-(5-amidino)benzimidazoyl]pyridine hydrochloride (compound 52).
A protocol similar to that described above was used to condense 2,6-pyridine dicarboxaldehyde with 4-amidino-1,2-phenylene diamine hydrochloride hydrate (17, 35) to give an 89% yield of a solid; mp, Ͼ300°C. A protocol similar to that described above was used for the condensation of 1,2-bis-(4-formylphenyl)ethane and 4-(N-isopropylamidino)-1,2-phenylene diamine (17, 35) and gave 75% yield of a purple solid; mp, Ͼ320°C. A protocol similar to that described above was used for the condensation of 4-(N-cyclopentylamidino)-1,2-phenylene diamine with 2,5-bis(4-formylphenyl) furan to give a 77% yield of a yellow solid; mp 295 to 297°C dec. furan was prepared by reduction of the bis-nitrile with DIBAL, which was added dropwise to a stirred solution of the bis-nitrile (1.68 g, 0.01 mol) in 150 ml of dry methylene chloride under nitrogen. The mixture was stirred for 15 min and allowed to reflux for 40 min, and the mixture was cooled and 100 ml of 1 M H 2 SO 4 was added dropwise while maintaining the solution temperature below 25°C. The methylene chloride layer was separated, the aqueous layer was extracted with 100 ml of methylene chloride, and the combined organic phases were washed with 20% NaHCO 3 and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, the residue was triturated with ether-hexane (1:1), and the white solid was filtered and dried in a vacuum to yield 1.2 g (69%); mp, 141 to 142°C. 1 Medium. Antifungal susceptibility testing was performed with RPMI 1640 medium (Sigma Chemical Co., St. Louis, Mo.) with glutamine but without sodium bicarbonate and buffered at pH 7.0 with 0.165 M morpholinepropanesulfonic acid.
In vitro susceptibility testing. Experiments for determination of MICs were performed by the broth macrodilution method according to the recommendations of the National Committee for Clinical Laboratory Standards (29) . The only difference compared to the standardized method was the choice of drug dilutions, which ranged from 100 to 0.09 g/ml. Briefly, this method specifies the use of an inoculum grown at 35°C and adjusted to a concentration of 0.5 ϫ 10 3 to 2.5 ϫ 10 3 CFU/ml, incubation of the culture at 35°C, and reading at 48 h for all yeasts except for C. neoformans, for which the results are interpreted at 72 h. The MIC was defined as the culture with the lowest drug concentration in which a visual turbidity less than or equal to 80% inhibition compared to that produced by the growth control tube was observed.
The methods used in experiments for determination of the minimum fungicidal concentration (MFC) were adapted from a method by McGinnis (26) . Briefly, 10-l aliquots from tubes with growth inhibition were plated onto Sabouraud agar plates. The lowest drug concentration that yielded three or fewer yeasts colonies was recorded as the MFC.
Molds were tested by the same method (29) but with the following modifications. Isolates were grown on Sabouraud dextrose agar at 30°C and were subcultured twice to ensure viability. After adequate sporulation occurred (after 4 to 12 days), conidia were harvested by flooding the colonies with a sterile solution of 0.85% NaCl and 0.05% Tween 80 in sterile distilled water. Inocula were prepared with a hemocytometer for counting and were then diluted with RPMI 1640 medium to obtain a final inoculum size of approximately 0.5 ϫ 10 3 to 2.5 ϫ 10 3 CFU/ml. The inoculum size was verified by plating an aliquot of the inoculum. The cultures were incubated at 30°C for 48 to 72 h or until growth in the control tube was visible.
In each experiment, the quality control included the testing of C. albicans A39 and C. neoformans var. neoformans H99 with fluconazole and amphotericin B.
RESULTS
The MICs of fluconazole and amphotericin B for C. albicans A39 and C. neoformans var. neoformans H99 were determined and served as positive controls for comparison with the experimental compounds. The MICs of fluconazole for C. albicans A39 and C. neoformans var. neoformans H99 were 0.25 and 2 g/ml, respectively. The MIC of amphotericin B was 1 g/ml for both isolates.
Pentamidine analogs. The in vitro activities of pentamidine and its analogues are summarized in Table 1 . Because the compounds appear to have fungicidal activity, both the MICs and the MFCs are reported in Table 1 .
It is noteworthy that pentamidine exhibits inhibitory activity that is comparable to those of both amphotericin B and fluconazole against both C. albicans and C. neoformans. In addition, the MFCs of pentamidine for both organisms were determined and they were found to be in the low concentration range. The variation of the alkyl chain length of pentamidine (compounds 1 and 3) resulted in a decrease in activity against C. albicans. Likewise, the two-carbon analogue (compound 1) had significantly reduced activity against C. neoformans compared to that of the parent molecule. Substitution of methoxy groups meta to the amidine moieties (compare compound 3 to compound 4 and compound 11 to compound 12) produced a reduction in activity against both organisms. Likewise, substitution of amino groups meta to the amidino groups gave a reduction in activity for the two-and three-carbon-chain analogs (compare compound 1 to compound 2 and compound 3 to compound 9). Substitution of chloro groups meta to the amidine moieties of pentamidine (compound 17) resulted in a reduction in activity against C. albicans, while it afforded a modest increase in activity against C. neoformans. Moving the amidino groups from the para to the meta positions with regard to the ether link produced a marked reduction in activity against C. albicans for the three-carbon analogues (compare compounds 3 and 7). However, the same alteration in the four carbon analogues (compare compounds 11 and 16) resulted in modestly increased activity against C. albicans and a decrease in potency against C. neoformans. Perhaps the most striking structure-activity effects occurred when the oxygens of pentamidine were replaced by nitrogens (compound 18). The activities of the amino isosteres showed a marked improvement over that of pentamidine against C. albicans and some improvement over that of pentamidine against C. neoformans. A similar result was noted with the three-carbonchain analogue (compare compounds 3 and 8) against C. albicans. A final observation for the pentamidine analogues was that the conversion of the cationic moieties from an amidino to an imidazolino group (compare compounds 11 and 14) produced an increase in antifungal activity against C. albicans. Pentamidine metabolites. Because pentamidine is rapidly metabolized in the body to at least seven primary metabolites, it was important to determine the antifungal effects of the known metabolites (Table 2) . When compared to pentamidine, the chain-hydroxylated metabolites (compounds 21 and 22) have approximately 10-fold reductions in their inhibitory activities against C. albicans and a 2-to 4-fold reductions in their inhibitory activities against C. neoformans. However, hydroxylation of either one (compound 27) or both (compound 23) of the amidine groups results in no significant activity against either organism when the compounds are used at 100 g/ml. Likewise, all metabolites resulting from the cleavage of an ether bond of pentamidine (compounds 24 to 26) have little or no activity at the highest dose tested.
Bis-benzimidazoles. A number of dication-substituted bisbenzimidazole derivatives have been shown to have excellent activities against P. carinii pneumonia in the rat model of disease (20) . For this reason we tested a large series of these compounds against C. albicans and C. neoformans (Table 3) . Structural variations of the compound were accomplished by altering the bridge connecting the 2-benzimidazolyl moieties (X in Table 3 ) and changes in the structure of the cationic groups (Y in Table 3 ). Overall, several very potent compounds were found in this series. In general the bis-benzimidazole bridged by an alkane chain showed poor antifungal activity (compounds 28 to 34). Only the benzimidazole joined by ethene bridge (compound 32) exhibited activity within a log range of the control drugs. Connecting 5-amidino-2-benzimadazoyl groups with a 2,5-furanyl link (compound 35) produced a compound with potent inhibitory activity against both isolates. In addition, the MFCs of the compound for C. albicans and C. neoformans were 0.78 and 3.12 g/ml, respectively. Alteration of the amidino cationic moieties (compounds 36 to 38) resulted in reduced activity. Isosteric replacement of the furan oxygen (compound 35) with nitrogen produced the corresponding pyrrole isostere (compound 39). Comparison of the isosteres (compounds 35 and 39) showed that they had very similar activities against both yeasts. In the case of the pyrrolelinked compounds, no difference was seen when the amidine was replaced by a 2-imidazoline moiety (compound 40). However, the other alterations of the cation groups (compounds 41 and 42) caused a decrease in activity. Methylation of the pyrrole nitrogen (compare compounds 39 and 43) had little effect on the activity against either organism. Interestingly, the cyclopentyl substitution of the amidino group (compound 45) on the N-methyl pyrrole-bridged compound produced one of the most potent inhibitors of C. neoformans (MIC, 0.19 g/ml).
Only one thiophene-linked compound was included in this study (compound 46). However, this compound was highly effective against C. albicans (MIC, 0.78 g/ml) and gave the highest activity of any of the compounds against C. neoformans (MIC, 0.19 g/ml) and the fungicidal concentrations for these yeasts were the same as the MICs.
Bridging the benzimidazole rings with a 1,4-phenyl group produced compounds (compounds 47 to 49) with various antifungal activities. The most remarkable finding within this group was the highly selective activity of the amidinosubstituted compound (compound 47) toward the two organisms. Compound 47 was highly effective against C. neoformans, while at 100 g/ml it was ineffective against C. albicans. The addition of methyl groups to the phenyl bridge to give a pxylene link (compound 50) resulted in decreased antifungal activity. Bridging of the benzimidazoles with a 2,6-pyridine linker gave two compounds (compounds 51 and 52) with interesting activities. At 100 g/ml, the amidine-substituted analogue (compound 51) showed no activity against either organism, while at 1.56 g/ml the imidazoline-substituted compound (compound 52) exhibited good activity against both organisms. This is in contrast to the furan-or pyrrole-bridged compounds, for which little difference in the activities of the imidazoline and amidine derivatives was noted.
The last five compounds in Table 3 (compounds 53 to 57) feature multiring bridges between the benzimidazole rings. All members of this group show good potency against both organisms. The most noteworthy of these compounds has a bridge consisting of a 2,5-benzo[b]furanyl group and amidino cationic moieties (compound 55). At concentrations under 1 g/ml the compound exhibits excellent inhibitory and fungicidal activities against both yeasts.
Broad-spectrum activities of selected compounds. In order to examine the spectrum of activity of these compounds, we selected, on the basis of compound activity and availability, com- 
DISCUSSION
Examination of the in vitro antifungal data for the series of 57 compounds described here reveals a number of structures that have activities equal to or greater than those of the control drugs (fluconazole and amphotericin B). The MICs were determined by the standardized methods of the National Committee for Clinical Laboratory Standards. On the other hand, the method of determination of MFCs was adapted to the method of determination of MICs and, although it is not standardized, showed the apparent fungicidal activities of some compounds, even though fluconazole does not show fungicidal activity by this assay. The potential fungicidal properties of these compounds will need to be assessed with animal models. Furthermore, selected compounds also appear to have a wide spectrum of activity, including fungicidal activity against fluconazole-resistant strains of C. albicans and C. neoformans. The only data detailing the toxicity of this class of compounds in humans are based on the findings with pentamidine (22, 34, 39) . While pentamidine has been associated with a number of adverse side effects, it has been proven to be effective in the treatment of the fungal infection pneumocystosis. It is encouraging that a large number of the pentamidine derivatives have been tested with animal models, and the findings indicate that the majority of the compounds are considerably less toxic than the parent compound (20, 23, 31, 34, 38) . Furthermore, it has been shown in the studies cited above that host cell toxicity and animal toxicity are not linked to the same structural refinements that impart enhanced antimicrobial activity. Given the in vitro antifungal activity and recent toxicology findings, it is likely that dication-substituted compounds with an acceptable antifungal activity to toxicity ratio could be developed.
While pentamidine appears to be a potent in vitro antifungal agent, the development of pentamidine as a therapeutic drug may be limited due in part to its known toxic side effects in humans but may be even more likely to be limited due to metabolism of the parent drug. For example, it has been demonstrated that pentamidine is readily metabolized to at least seven primary metabolites (7) . It can be seen from the data in Table 2 that all of the primary metabolites of pentamidine have reduced antifungal activity and that the metabolites resulting from the breaking of the ether bond or hydroxylation of an amidino nitrogen are devoid of activity. In addition to the loss of activity, recent work in our laboratory indicates that certain metabolites have increased toxicity (unpublished data). Unfortunately, metabolic breakup of the parent molecule may be a problem encountered with many of the direct pentamidine analogues, especially those that contain an ether bond in the bridge between the cationic moieties. An advantage to the bis-benzimidazole compounds would be the lack of a cleavage product resulting from primary metabolism.
A key to the further development of these antifungal compounds will be establishment of their mechanisms of action. It has been proposed that the activity of this class of compounds against G. lamblia is a result of their binding in the minor grooves of DNA followed by inhibition of topoisomerase II (4) . While this mechanism appears to be likely for G. lamblia, no direct correlation was found between the anti-topoisomerase II inhibition of these compounds and their activity against Cryptosporidium parvum (9) or P. carinii (16) . It has been hypothesized that the primary cellular target of pentamidine in the yeast Saccharomyces cerevisiae is the mitochondrion (25) , and more recently, it has been suggested that these compounds have an effect on another fungus, P. carinii, due to their DNA binding followed by inhibition of an endo-or exonuclease (19) . A major source of the problem in determining the mechanisms of action against P. carinii and C. parvum is the lack of effective in vitro culture systems. Such a problem would not exist for most classical fungal organisms since they are readily grown in vitro. Studies to determine the mechanisms of action of these compounds against selected fungi should have a high probability of success.
In conclusion, the data presented in this report indicate the potential of dicationic molecules as antifungal agents. A number of new molecules have been identified from this initial study of structure-function relationships, and these new molecules require future synthesis and antifungal testing. An example of this need to focus our attention is the development of a complete series of compounds with a thiophene as the linking group (compound 46). It is clear that further studies on the structure-activity relationships, mechanisms of action and toxicities, and in vivo efficacies of these compounds are warranted to determine their clinical potential. 
